Loading...

BMEA BIOMEA FUSION INC Investor Conferences 8-K Filing

BM F

BM

BIOMEA FUSION INC

(BMEA)

2024 8-K

Show Summary

Summary

Equity Offerings

Equity Offerings

Product Expansion

Financial Statements

Financial Results

Management Changes

Management Change

Clinical Trial Results

Preclinical Data Update

Financial Results

FDA Approval Update

Earnings Reports

Annual Meeting Voting Results

Other Special Situation

Earnings Reports

Earnings Reports

Presentation of Patient Coh...

Presentation at J.P. Morgan...

Earnings Reports

Earnings Reports

Product Updates

Earnings Reports

Earnings Reports

Underwriting Agreement

Clinical Trial Data Announc...

Financial Results Announcement

Press Release and Presentation

External Links:

Biomea Fusion, Inc. held a conference call on October 30, 2024, to discuss preclinical data on their drug Icovamenib (BMF-219) and introduced a new candidate BMF-650, with a presentation and press release available for investors.

AI Assistant

BIOMEA FUSION INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.